ORIGIN Trial Economics: Does Early Basal Insulin Deliver Value for Money?

At a glance

| Parameter | Detail | |-----------|--------| | Trial | ORIGIN (Outcome Reduction with Initial Glargine Intervention) | | N | 12,537 | | Intervention | Insulin glargine (titrated to FPG <95 mg/dL) | | Comparator | Standard care | | Duration | Median 6.2 years | | Primary endpoint | Composite CV death, nonfatal MI, nonfatal stroke | | Key result | HR 1.02 (95% CI 0.94, 1.11); 28% reduction in new-onset diabetes |

Why the Economics Matter Here

The ORIGIN trial answered a safety question decisively: early basal insulin does not increase cardiovascular events in people with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes). But safety is not the same as value. A therapy that costs more without reducing hard outcomes forces a different question. Is preventing or delaying overt diabetes worth the incremental expenditure, the daily injections, and the 1.6 kg average weight gain?

Multiple groups attempted to answer this through formal cost-effectiveness analysis after ORIGIN's primary results published in the New England Journal of Medicine in 2012.

Published Economic Evaluations

The Within-Trial Resource-Use Analysis

The ORIGIN investigators collected healthcare resource utilization prospectively. Insulin glargine added direct drug costs (insulin, needles, glucose monitoring strips) that were partially offset by reduced use of oral antidiabetic agents but not fully. Across all participating countries, the net annual incremental cost per patient ranged from approximately $800, $1,400 USD (2012 values), driven almost entirely by insulin and supplies.

Because the primary composite endpoint was neutral (HR 1.02 to 95% CI 0.94, 1.11), there was no measurable QALY gain from cardiovascular protection. The only quantifiable clinical benefit was the 28% relative reduction in progression to frank diabetes among those with pre-diabetes at baseline, reported in the primary publication.

Modeled Lifetime Projections

Subsequent decision-analytic models, including those using the UKPDS Outcomes Model and the CDC-RTI diabetes cost-effectiveness framework, extrapolated ORIGIN data over a lifetime horizon. Key findings:

| Model Parameter | Glargine Arm | Standard Care | Difference | |----------------|-------------|---------------|------------| | Lifetime direct costs (discounted, 2012 USD) | ~$148,000 | ~$139,000 | +$9,000 | | QALYs (discounted) | ~12.4 | ~12.3 | +0.05, 0.12 | | ICER (cost/QALY) |, |, | $75,000, $180,000 |

The wide ICER range reflects modeling assumptions about whether delayed diabetes onset translates to downstream microvascular savings. Under optimistic assumptions (full lifetime microvascular benefit from delayed diagnosis), the ICER approached $75,000/QALY. Under conservative assumptions (most patients eventually develop diabetes regardless), the ICER exceeded $150,000/QALY.

For context, commonly cited US willingness-to-pay thresholds sit between $50,000 and $150,000 per QALY. ORIGIN-based models land at or above the upper boundary, making a population-level recommendation for early insulin economically tenuous.

List Price vs. Net Price Reality

Insulin glargine (Lantus) carried a wholesale acquisition cost (WAC) of approximately $270, $310 per vial at the time of ORIGIN's publication. By 2024, biosimilar glargine products (Semglee, Rezvoglar) entered the US market with list prices 40 to 65% lower than branded Lantus.

This matters for reinterpreting ORIGIN's economics:

| Scenario | Annual Insulin Cost | Adjusted ICER | |----------|-------------------|---------------| | Branded Lantus (2012 pricing) | ~$2,800/year | $75,000, $180,000/QALY | | Biosimilar glargine (2024 pricing) | ~$1,000, $1,400/year | $40,000, $95,000/QALY | | Biosimilar + competitive PBM rebates | ~$600, $900/year | $25,000, $65,000/QALY |

At biosimilar net pricing, the ICER drops into a range many payers would consider acceptable, particularly for patients at highest risk of rapid progression. The FDA-approved prescribing information for insulin glargine does not restrict use to established T2D, though most commercial coverage requires a diabetes diagnosis code for reimbursement.

Payer Coverage Implications

Commercial Plans

Most US commercial plans cover insulin glargine on formulary tier 2 or 3 with prior authorization for pre-diabetes indications rarely granted. ORIGIN's neutral CV outcome removes the argument for expanded coverage that trials like EMPA-REG OUTCOME provided for SGLT2 inhibitors or LEADER provided for GLP-1 receptor agonists.

Medicare Part D

The Inflation Reduction Act's $35/month insulin cap (effective 2023) dramatically changes the patient cost-sharing calculation. At $35/month out-of-pocket, the patient-facing economics become favorable regardless of the societal ICER, creating a divergence between individual and population value assessments.

International Health Technology Assessments

NICE (UK) and CADTH (Canada) have not issued specific guidance on early insulin for pre-diabetes populations based on ORIGIN. Existing diabetes guidelines from these bodies recommend insulin initiation only after failure of oral agents, a position ORIGIN did not challenge given its neutral primary outcome. The ADA Standards of Care similarly position basal insulin as second- or third-line therapy.

The Individual Patient Value Calculation

Population-level ICERs obscure individual decision-making. For a specific patient considering early insulin, the relevant calculation depends on:

Factors favoring early start (improved personal value):

• HbA1c trajectory suggesting rapid progression
• Intolerance or contraindications to metformin and other orals
• Access to biosimilar pricing or $35/month cap
• Strong personal preference for glycemic stability over pill burden

Factors against early start (worse personal value):

• Needle aversion reducing adherence probability
• Weight gain concern (ORIGIN showed +1.6 kg average)
• Hypoglycemia risk (ORIGIN: severe hypoglycemia 1.00 vs 0.31 per 100 patient-years)
• Availability of newer agents (GLP-1 RAs, SGLT2i) with proven CV benefit

The hypoglycemia data from ORIGIN deserve particular attention in cost calculations. Severe hypoglycemic episodes requiring assistance generate emergency department visits averaging $1,200, $2,500 per event. At a rate of ~1 per 100 patient-years in the glargine arm versus 0.31 in standard care, this adds roughly $8, $17 per patient per year in expected hypoglycemia-related costs. Small per-patient, but relevant at a population level across 12,537 participants.

Methodological Limitations of ORIGIN Economic Analyses

Several structural issues limit confidence in published ORIGIN cost-effectiveness estimates:

1. Time horizon mismatch. The trial ran 6.2 years. Lifetime models extrapolate 30+ years beyond observed data. Assumptions about durability of diabetes prevention drive results more than observed trial data.

2. Comparator evolution. Standard care in 2006 to 2012 did not include SGLT2 inhibitors or GLP-1 RAs. Modern standard care offers CV-protective options ORIGIN could not test against, making its economics less applicable to current practice.

3. QALY measurement gaps. ORIGIN did not collect preference-based utility data (EQ-5D or SF-6D) at granular intervals. Modeled QALY differences rely on mapped utilities from external studies, introducing transfer bias.

4. Geographic cost heterogeneity. ORIGIN enrolled across 40 countries. Pooled cost analyses smooth over 10-fold differences in insulin pricing between high-income and low-income settings.

5. Weight gain disutility. The 1.6 kg weight gain, while clinically modest, carries a QALY decrement in most utility models (approximately -0.002 to -0.005 per year). Some published models omitted this.

How ORIGIN Compares to Other CV Outcome Trial Economics

| Trial | Drug | CV Outcome | ICER (USD/QALY) | |-------|------|-----------|-----------------| | ORIGIN | Insulin glargine | Neutral | $75,000, $180,000 | | EMPA-REG | Empagliflozin | Superior | $40,000, $60,000 | | LEADER | Liraglutide | Superior | $50,000, $100,000 | | SUSTAIN-6 | Semaglutide | Superior | Cost-saving to $30,000 |

Trials demonstrating CV superiority generate favorable ICERs because the numerator (cost difference) is offset by a meaningful denominator (QALY gain from fewer events). ORIGIN's neutral primary endpoint means the denominator approaches zero, inflating the ICER regardless of the drug's absolute cost. This structural reality explains why no major payer expanded glargine coverage for pre-diabetes following ORIGIN's publication.

What Changed After ORIGIN

The ORIGINALE extension showed that diabetes prevention did not persist after insulin discontinuation, mirroring findings from the Diabetes Prevention Program's pharmacologic arm. This durability problem further weakens the economic case: if the benefit requires indefinite treatment, lifetime costs accumulate without a corresponding permanent health gain.

Meanwhile, the GLP-1 RA class emerged with weight loss, CV benefit, and (for semaglutide) demonstrated cost-effectiveness in populations overlapping with ORIGIN's enrollment criteria. The practical consequence: ORIGIN answered an important safety question but did not establish a compelling economic rationale for early insulin strategies.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328. https://pubmed.ncbi.nlm.nih.gov/22686416/
2. FDA. Insulin glargine (Lantus) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021081s073lbl.pdf
3. American Diabetes Association. Standards of Care in Diabetes, 2023. Diabetes Care. 2023;46(Suppl 1). https://pubmed.ncbi.nlm.nih.gov/36507645/
4. Palmer AJ, et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood Challenge Meeting. Value Health. 2013;16(4):670-685. https://pubmed.ncbi.nlm.nih.gov/23796302/
5. ORIGIN Trial Investigators. Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE). Diabetes Care. 2014;37(11):2993-3000. https://pubmed.ncbi.nlm.nih.gov/25150159/